Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0213)
Name
Bazedoxifene
Synonyms
Bazedoxifene; 198481-32-2; Bazedoxifene [INN]; TSE-424; Bazedoxifene free base; 1H-Indol-5-ol, 1-[[4-[2-(hexahydro-1H-azepin-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methyl-; Q16TT9C5BK; 1-(4-(2-(azepan-1-yl)ethoxy)benzyl)-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol; CHEMBL46740; 198481-32-2 (free base); 1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol; WAY 140424; Bazedoxifeno; C30H34N2O3; 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol; 1H-Indol-5-ol, 1-((4-(2-(hexahydro-1H-azepin-1-yl)ethoxy)phenyl)methyl)-2-(4-hydroxyphenyl)-3-methyl-; UNII-Q16TT9C5BK; Bazedoxifeno [INN-Spanish]; 1-{4-[2-(azepan-1-yl)ethoxy]benzyl}-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol; BAZEDOXIFENE [MI]; BAZEDOXIFENE [VANDF]; SCHEMBL41935; BAZEDOXIFENE [WHO-DD]; GTPL7355; BAZEDOXIFENE [EMA EPAR]; DTXSID70173593; CHEBI:135947; UCJGJABZCDBEDK-UHFFFAOYSA-N; EX-A5409; HY-A0031; BDBM50099585; NSC823462; AKOS030255808; AK R215 COMPONENT BAZEDOXIFENE; AK-R215 COMPONENT BAZEDOXIFENE; CS-0932; DB06401; NSC-823462; SB19326; 1-[[4-[2-(AZEPAN-1-YL)ETHOXY]PHENYL]METHYL]-2-(4-HYDROXYPHENYL)-3-METHYL-INDOL-5-OL; 1-((4-(2-Hexahydro-1H-azepin-1-yl)ethoxy)phenyl)methyl)-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol; AS-78494; US8815934, No. 98; A15019; D94589; AB01566901_01; A879977; EN300-20600169; J-012822; Q4875166; 1-({4-[2-(azepan-1-yl)ethoxy]phenyl}methyl)-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol; 1-(P-(2-(HEXAHYDRO-1H-AZEPIN-1-YL)ETHOXY)BENZYL)-2-(P-HYDROXYPHENYL)-3-METHYLINDOL-5-OL

    Click to Show/Hide
Status
Approved
Drug Type
Small molecular drug
Structure
Formula
C30H34N2O3
IUPAC Name
1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol
Canonical SMILES
CC1=C(N(C2=C1C=C(C=C2)O)CC3=CC=C(C=C3)OCCN4CCCCCC4)C5=CC=C(C=C5)O
InChI
InChI=1S/C30H34N2O3/c1-22-28-20-26(34)12-15-29(28)32(30(22)24-8-10-25(33)11-9-24)21-23-6-13-27(14-7-23)35-19-18-31-16-4-2-3-5-17-31/h6-15,20,33-34H,2-5,16-19,21H2,1H3
InChIKey
UCJGJABZCDBEDK-UHFFFAOYSA-N
PubChem CID
154257
TTD Drug ID
D0JY8T
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Responsed Disease Breast cancer ICD-11: 2C60
 Disease Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
Cell proliferation
In Vitro Model HT-1080 cells Fibrosarcoma Homo sapiens CVCL_0317
U2OS cells Osteosarcoma Homo sapiens CVCL_0042
MDA-MB-231 cells Breast adenocarcinoma Homo sapiens CVCL_0062
HEK-293T cells Normal Homo sapiens CVCL_0063
NCI-H1299 cells Lung large cell carcinoma Homo sapiens CVCL_0060
A-549 cells Lung adenocarcinoma Homo sapiens CVCL_0023
T98G cells Glioblastoma Homo sapiens CVCL_0556
Caki-1 cells Clear cell renal cell carcinoma Homo sapiens CVCL_0234
A-375 cells Amelanotic melanoma Homo sapiens CVCL_0132
4T1 cells Mammary carcinoma Mus musculus CVCL_0125
EO771 cells Breast carcinoma Mus musculus CVCL_GR23
In Vivo Model
N2 Bristol (wild-type) nematodes were maintained on nematode growth media (NGM) plates seeded with bacteria (E. coliOP50) at 20. Experiments with dihomo--linolenic acid (DGLA) were performed using NGM plates formulated with 0.1% Tergitol NP40 (Sigma Chemicals) and 0.125 mM DGLA sodium salt (NuChek Prep, Inc.) or Tergitol alone (vehicle). Dry plates were seeded with OP50 and then three days later ferrostatin-1 or bazedoxifene were dissolved into the plates at a final concentration of 150 uM and allowed to dry for 30 min, before ~50 synchronized L1 larvae were transferred to each plate. Sterility was scored 72-96 h later, as determined by light microscopic examination of uterine embryos.

    Click to Show/Hide
Response regulation The FDA-approved drug bazedoxifene acts as a potent radical trapping antioxidant inhibitor of ferroptosis both in vitro and in vivo. Bazedoxifene potently suppressed ferroptosis in MDA-MB-231, E0771, and 4T1 breast cancer cell lines which do not express the estrogen receptor.
References
Ref 1 A compendium of kinetic modulatory profiles identifies ferroptosis regulators. Nat Chem Biol. 2021 Jun;17(6):665-674. doi: 10.1038/s41589-021-00751-4. Epub 2021 Mar 8.